Home
Drugs
Filgrastim
Clinical Trials

Clinical Trials Related to Filgrastim

Related studies linked through entity extraction aliases.

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL

Status: RECRUITING
Phase: PHASE3

Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1/PHASE2

Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma

Status: WITHDRAWN
Phase: PHASE1

A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

Comparison of Quality and Quantity of M-PRP Cellular Content Filgrastim vs. Pegfilgrastim

Status: COMPLETED
Phase: N/A

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

Status: RECRUITING
Phase: PHASE2

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Status: RECRUITING
Phase: PHASE1/PHASE2

GM-CLAG in Relapsed/Refractory FLT3-mutated AML

Status: WITHDRAWN
Phase: PHASE1

Venetoclax to Augment Epigenetic Modification and Chemotherapy

Status: RECRUITING
Phase: PHASE1

Cryopreserved MMUD BM With PTCy for Hematologic Malignancies

Status: WITHDRAWN
Phase: PHASE1

Off-the-shelf NK Cells + SCT for Myeloid Malignancies

Status: COMPLETED
Phase: PHASE2

hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)

Status: RECRUITING
Phase: PHASE2

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

Status: RECRUITING
Phase: PHASE1/PHASE2

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1

A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy

Status: COMPLETED
Phase: PHASE4

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Status: TERMINATED
Phase: PHASE1/PHASE2

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

Status: RECRUITING
Phase: PHASE2